Last reviewed · How we verify
HRS-7535 Tablets — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
HRS-7535 Tablets (HRS-7535 Tablets) — Shandong Suncadia Medicine Co., Ltd.. HRS-7535 is an investigational small molecule with unknown mechanism of action in Phase 3 development.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HRS-7535 Tablets TARGET | HRS-7535 Tablets | Shandong Suncadia Medicine Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HRS-7535 Tablets CI watch — RSS
- HRS-7535 Tablets CI watch — Atom
- HRS-7535 Tablets CI watch — JSON
- HRS-7535 Tablets alone — RSS
Cite this brief
Drug Landscape (2026). HRS-7535 Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs-7535-tablets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing